Taiwan Biomaterial Co., Ltd. (TPEX:6649)
73.80
+3.30 (4.68%)
Oct 9, 2025, 1:30 PM CST
Taiwan Biomaterial Revenue
Taiwan Biomaterial had revenue of 33.79M TWD in the quarter ending June 30, 2025, with 58.43% growth. This brings the company's revenue in the last twelve months to 157.98M, up 141.09% year-over-year. In the year 2024, Taiwan Biomaterial had annual revenue of 96.57M with 32.59% growth.
Revenue (ttm)
157.98M
Revenue Growth
+141.09%
P/S Ratio
19.62
Revenue / Employee
n/a
Employees
35
Market Cap
3.10B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 96.57M | 23.74M | 32.59% |
Dec 31, 2023 | 72.84M | -54.47M | -42.79% |
Dec 31, 2022 | 127.31M | 85.63M | 205.48% |
Dec 31, 2021 | 41.67M | 23.60M | 130.56% |
Dec 31, 2020 | 18.08M | 1.53M | 9.26% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Lumosa Therapeutics | 37.25M |
Oneness Biotech | 112.57M |
Polaris Group | 64.02M |
Center Laboratories | 1.60B |